Detail akcie Tectonic Therap Rg online

Business Summary: Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tectonic Therapeutic Inc revenues was not reported. Net loss increased 20% to $54.9M. Higher net loss reflects Biological Product segment loss increase of 42% to $62.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.10 to -$3.01.